Weighted Average Number of Shares Outstanding, Basic of GYRE THERAPEUTICS, INC. from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
GYRE THERAPEUTICS, INC. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • GYRE THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 89,344,622, a 5% increase year-over-year.
  • GYRE THERAPEUTICS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 89,344,622, a 5% increase from 2024.
  • GYRE THERAPEUTICS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 85,094,948, a 29% increase from 2023.
  • GYRE THERAPEUTICS, INC. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 65,831,675, a 3.5% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

GYRE THERAPEUTICS, INC. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 89,344,622 +4,249,674 +5% 01 Oct 2025 31 Dec 2025 10-K 13 Mar 2026 2025 FY
Q3 2025 90,850,040 +5,206,394 +6.1% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 89,119,344 +3,616,941 +4.2% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 86,420,530 +3,154,651 +3.8% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 85,094,948 +19,263,273 +29% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2026 2025 FY
Q3 2024 85,643,646 +22,055,527 +35% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 85,502,403 +21,914,284 +34% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 83,265,879 +19,677,760 +31% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 65,831,675 +2,243,556 +3.5% 01 Oct 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
Q3 2023 63,588,119 +32,103,577 +102% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 63,588,119 +32,111,066 +102% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 63,588,119 +32,132,029 +102% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 63,588,119 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 31,484,542 +104,787 +0.33% 01 Jul 2022 30 Sep 2022 10-Q 26 Oct 2023 2023 Q3
Q2 2022 31,477,053 +128,451 +0.41% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 31,456,090 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q3 2021 31,379,755 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 31,348,602 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q3 2013 33,644,256 +150,150 +0.45% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2013 2013 Q3
Q2 2013 33,626,980 +217,639 +0.65% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2013 2013 Q2
Q1 2013 33,616,342 +226,056 +0.68% 01 Jan 2013 31 Mar 2013 10-Q 08 May 2013 2013 Q1
Q4 2012 33,609,867 +227,227 +0.68% 01 Oct 2012 31 Dec 2012 10-K 14 Mar 2014 2013 FY
Q3 2012 33,494,106 +116,232 +0.35% 01 Jul 2012 30 Sep 2012 10-K 14 Mar 2014 2013 FY
Q2 2012 33,409,341 +2,684,114 +8.7% 01 Apr 2012 30 Jun 2012 10-K 14 Mar 2014 2013 FY
Q1 2012 33,390,286 +4,394,226 +15% 01 Jan 2012 31 Mar 2012 10-K 14 Mar 2014 2013 FY
Q4 2011 33,382,640 01 Oct 2011 31 Dec 2011 10-K 15 Mar 2013 2012 FY
Q3 2011 33,377,874 +4,755,687 +17% 01 Jul 2011 30 Sep 2011 10-K 15 Mar 2013 2012 FY
Q2 2011 30,725,227 +2,215,608 +7.8% 01 Apr 2011 30 Jun 2011 10-K 15 Mar 2013 2012 FY
Q1 2011 28,996,060 01 Jan 2011 31 Mar 2011 10-K 15 Mar 2013 2012 FY
Q3 2010 28,622,187 01 Jul 2010 30 Sep 2010 10-Q 03 Nov 2011 2011 Q3
Q2 2010 28,509,619 01 Apr 2010 30 Jun 2010 10-Q 09 Aug 2011 2011 Q2

GYRE THERAPEUTICS, INC. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 89,344,622 +4,249,674 +5% 01 Jan 2025 31 Dec 2025 10-K 13 Mar 2026 2025 FY
2024 85,094,948 +19,263,273 +29% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2026 2025 FY
2023 65,831,675 +2,243,556 +3.5% 01 Jan 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
2022 63,588,119 +32,947,142 +108% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 30,640,977 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2012 33,476,316 +1,839,033 +5.8% 01 Jan 2012 31 Dec 2012 10-K 15 Mar 2013 2012 FY
2011 31,637,283 +3,093,875 +11% 01 Jan 2011 31 Dec 2011 10-K 15 Mar 2013 2012 FY
2010 28,543,408 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.